Eli Lilly reported first‑quarter 2026 results that surpassed expectations across the board. Worldwide revenue rose 56% to $19.799 billion, driven by a 65% increase in volume that offset a 13% decline in realized prices. Adjusted earnings per share climbed to $8.55, a 156% year‑over‑year gain that beat consensus estimates of $6.73–$7.06 by $1.49–$1.89 per share. Diluted earnings per share reached $8.26, up 170% from the same quarter a year earlier.
The company’s flagship obesity and diabetes products continued to dominate the earnings story. Mounjaro and Zepbound generated $13.4 billion in key‑product revenue, with Mounjaro alone reporting $8.662 billion and Zepbound $4.160 billion. The launch of the oral GLP‑1 weight‑loss pill Foundayo, which began shipping on April 9, added a new revenue stream and broadened the patient base for GLP‑1 therapies. Management highlighted that manufacturing scale has allowed Lilly to capture market share despite pricing pressure, and that the 2026 guidance reflects a strategy of trading pricing power for volume expansion in Medicare and international markets.
Operating cash flow more than doubled to $5.3 billion, while research and development spending increased 28% to $3.5 billion and marketing, selling and administrative expenses rose 19% to $2.9 billion. Gross margin contracted by 0.6–0.9 percentage points year‑over‑year, largely due to lower realized prices, but the company’s non‑GAAP performance margin expanded to 50%, reflecting the strong mix of high‑margin products and effective cost control.
Eli Lilly raised its full‑year 2026 revenue guidance to $82 billion–$85 billion, up from the prior $80 billion–$83 billion range, and adjusted EPS guidance to $35.50–$37.00, an increase from the previous $33.50–$35.00. The upward revision signals management confidence in continued volume growth of its obesity and diabetes portfolio and the successful market entry of Foundayo.
Management emphasized the company’s momentum, noting that “2026 is off to a strong start. During the quarter, we delivered robust revenue growth, advanced our pipeline across all four therapeutic areas, announced multiple business development transactions, and invested to drive our future growth.” They added that the FDA approval of Foundayo “will meaningfully expand the number of people who can benefit from GLP‑1s,” and that “this marks the fifth or sixth consecutive quarter of high revenue growth, a rare achievement for a company of Eli Lilly’s size.”
The results reinforce Eli Lilly’s position as a leader in the obesity and diabetes markets, with a growing pipeline and a strategy that balances pricing power with volume expansion. The strong earnings beat, combined with the raised guidance, underscores the company’s execution capability and its ability to navigate pricing pressures while maintaining robust growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.